PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis and/or HCC-Hepatocellular carcinoma) and for comparative purpose a cohort of subjects with diabetes and/or obesity and/or other risk factors (i.e. psoriasis, IBD (inflammatory bowel disease), dyslipidemia) without NAFLD in order to have a clinical phenotypical characterization and the collection of biological specimens. We will collect clinical data, biological samples and imaging results in order to perform future cross-sectional studies and/or longitudinal studies for elucidating pathways of the disease and develop and validate biomarkers for diagnosis, prognosis and monitoring liver disease and comorbidities in order to contribute to precision medicine in this field.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years

• Clinical phenotype of NAFLD (simple steatosis, NASH, metabolic cirrhosis, NAFLD-HCC) based on any of:

• Liver biopsy providing histological evidence of NAFLD or,

• Biochemical and/or radiological findings consistent with NAFLD

• Average alcohol consumption ≤21/14 units/week (males/females) in preceding 6 months and no history of sustained excessive consumption of alcohol in past 5 years.

• Clearance of HCV infection with new DAAs drugs with a SVR (sustained virological response) period \> 6 months

• Presence of risk factors for NAFLD (i.e. diabetes, metabolic syndrome, obesity, psoriasis) and absence of fatty liver at US

Locations
Other Locations
Italy
Catholic University of Rome, Fondazione Policlinico Gemelli IRCCS
RECRUITING
Roma
Contact Information
Primary
LUCA MIELE, MD, PhD
luca.miele@policlinicogemelli.it; luca.miele@unicatt.it
+390631051
Time Frame
Start Date: 2019-09-01
Estimated Completion Date: 2035-12-31
Participants
Target number of participants: 5000
Sponsors
Leads: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

This content was sourced from clinicaltrials.gov